GlycoMimetics (GLYC) Lowered to Hold at BidaskClub

Man Group plc increased its stake in GlycoMimetics by 627.1% in the 3rd quarter. Man Group plc now owns 411,995 shares of the biotechnology …

GlycoMimetics Inc logoBidaskClub downgraded shares of GlycoMimetics (NASDAQ:GLYC) from a buy rating to a hold rating in a research report report published on Wednesday morning, BidAskClub reports.

Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of GlycoMimetics from a hold rating to a sell rating in a report on Thursday, March 7th. ValuEngine lowered shares of GlycoMimetics from a strong-buy rating to a buy rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright assumed coverage on shares of GlycoMimetics in a research note on Tuesday, December 18th. They set a buy rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $23.75.

GlycoMimetics stock traded up $0.21 during mid-day trading on Wednesday, hitting $12.21. 31,961 shares of the company were exchanged, compared to its average volume of 262,054. The company has a market capitalization of $518.04 million, a price-to-earnings ratio of -10.35 and a beta of 2.76. GlycoMimetics has a 12-month low of $8.29 and a 12-month high of $19.20.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Research analysts anticipate that GlycoMimetics will post -1.19 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the business. Redmile Group LLC lifted its holdings in shares of GlycoMimetics by 0.9% during the third quarter. Redmile Group LLC now owns 2,048,147 shares of the biotechnology company’s stock worth $29,493,000 after purchasing an additional 18,800 shares during the period. Jefferies Group LLC acquired a new stake in GlycoMimetics in the 3rd quarter valued at $2,458,000. Man Group plc increased its stake in GlycoMimetics by 627.1% in the 3rd quarter. Man Group plc now owns 411,995 shares of the biotechnology company’s stock valued at $5,933,000 after buying an additional 355,329 shares during the last quarter. Vanguard Group Inc increased its stake in GlycoMimetics by 1.6% in the 3rd quarter. Vanguard Group Inc now owns 1,691,550 shares of the biotechnology company’s stock valued at $24,358,000 after buying an additional 26,951 shares during the last quarter. Finally, MetLife Investment Advisors LLC increased its stake in GlycoMimetics by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 25,810 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 9,175 shares during the last quarter.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: What is a back-end load?

Receive News & Ratings for GlycoMimetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlycoMimetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BidaskClub Upgrades GlycoMimetics (GLYC) to “Buy”

Man Group plc increased its holdings in GlycoMimetics by 627.1% in the third quarter. Man Group plc now owns 411,995 shares of the biotechnology …

GlycoMimetics Inc logoBidaskClub upgraded shares of GlycoMimetics (NASDAQ:GLYC) from a hold rating to a buy rating in a research report released on Wednesday, February 27th.

Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded GlycoMimetics from a hold rating to a buy rating and set a $12.00 price objective on the stock in a report on Tuesday, January 8th. ValuEngine cut GlycoMimetics from a strong-buy rating to a buy rating in a research report on Wednesday, January 2nd. HC Wainwright started coverage on GlycoMimetics in a research report on Tuesday, December 18th. They set a buy rating and a $24.00 target price on the stock. Finally, Roth Capital set a $35.00 price objective on GlycoMimetics and gave the stock a buy rating in a research report on Monday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company has an average rating of Buy and an average target price of $23.75.

GLYC traded up $0.23 during trading on Wednesday, hitting $13.10. 167,425 shares of the stock were exchanged, compared to its average volume of 242,022. The company has a market capitalization of $555.60 million, a P/E ratio of -11.10 and a beta of 2.76. GlycoMimetics has a 1 year low of $8.29 and a 1 year high of $19.20.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Equities analysts anticipate that GlycoMimetics will post -1.19 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Redmile Group LLC raised its stake in shares of GlycoMimetics by 0.9% during the 3rd quarter. Redmile Group LLC now owns 2,048,147 shares of the biotechnology company’s stock valued at $29,493,000 after buying an additional 18,800 shares during the last quarter. Jefferies Group LLC purchased a new position in GlycoMimetics in the third quarter valued at $2,458,000. Man Group plc increased its holdings in GlycoMimetics by 627.1% in the third quarter. Man Group plc now owns 411,995 shares of the biotechnology company’s stock valued at $5,933,000 after buying an additional 355,329 shares during the last quarter. Vanguard Group Inc boosted its stake in GlycoMimetics by 1.6% in the third quarter. Vanguard Group Inc now owns 1,691,550 shares of the biotechnology company’s stock valued at $24,358,000 after acquiring an additional 26,951 shares in the last quarter. Finally, MetLife Investment Advisors LLC boosted its stake in GlycoMimetics by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 25,810 shares of the biotechnology company’s stock valued at $372,000 after acquiring an additional 9,175 shares in the last quarter.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: Why Net Income is Important to Investors

Receive News & Ratings for GlycoMimetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlycoMimetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

GlycoMimetics (NASDAQ:GLYC) Lowered to “Hold” at BidaskClub

Man Group plc grew its holdings in GlycoMimetics by 627.1% during the third quarter. Man Group plc now owns 411,995 shares of the biotechnology …

GlycoMimetics Inc logoBidaskClub cut shares of GlycoMimetics (NASDAQ:GLYC) from a buy rating to a hold rating in a research report sent to investors on Saturday, March 9th.

GLYC has been the subject of several other reports. ValuEngine downgraded shares of GlycoMimetics from a strong-buy rating to a buy rating in a report on Wednesday, January 2nd. HC Wainwright began coverage on shares of GlycoMimetics in a report on Tuesday, December 18th. They set a buy rating and a $24.00 price target for the company. Finally, Zacks Investment Research downgraded shares of GlycoMimetics from a hold rating to a sell rating in a report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. GlycoMimetics has an average rating of Hold and an average target price of $23.75.

NASDAQ GLYC opened at $12.54 on Friday. The firm has a market capitalization of $541.35 million, a price-to-earnings ratio of -10.63 and a beta of 2.76. GlycoMimetics has a 52-week low of $8.29 and a 52-week high of $19.20.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Sell-side analysts predict that GlycoMimetics will post -1.19 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of GLYC. Dimensional Fund Advisors LP bought a new stake in shares of GlycoMimetics during the third quarter worth approximately $5,598,000. Man Group plc grew its holdings in GlycoMimetics by 627.1% during the third quarter. Man Group plc now owns 411,995 shares of the biotechnology company’s stock valued at $5,933,000 after purchasing an additional 355,329 shares during the period. Northern Trust Corp grew its holdings in GlycoMimetics by 392.4% during the second quarter. Northern Trust Corp now owns 416,092 shares of the biotechnology company’s stock valued at $6,712,000 after purchasing an additional 331,581 shares during the period. Hudson Bay Capital Management LP grew its holdings in GlycoMimetics by 105.9% during the fourth quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $3,315,000 after purchasing an additional 180,000 shares during the period. Finally, Jefferies Group LLC acquired a new position in GlycoMimetics during the third quarter valued at approximately $2,458,000.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: How can you know how many shares are floating?

Receive News & Ratings for GlycoMimetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlycoMimetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

GlycoMimetics (GLYC) Downgraded by ValuEngine

WINTON GROUP Ltd acquired a new position in GlycoMimetics during the third quarter valued at approximately $186,000. Voya Investment …

GlycoMimetics logoGlycoMimetics (NASDAQ:GLYC) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday, February 4th.

A number of other analysts have also commented on the stock. Roth Capital set a $35.00 price objective on shares of GlycoMimetics and gave the company a “buy” rating in a research note on Monday, November 5th. BidaskClub upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research cut GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 30th. Finally, HC Wainwright began coverage on GlycoMimetics in a research report on Tuesday, December 18th. They set a “buy” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $23.75.

GlycoMimetics stock traded up $0.13 during trading on Monday, reaching $11.21. The company had a trading volume of 362 shares, compared to its average volume of 253,879. GlycoMimetics has a 12-month low of $8.29 and a 12-month high of $26.05. The company has a market cap of $477.96 million, a price-to-earnings ratio of -9.91 and a beta of 2.82.

Large investors have recently bought and sold shares of the business. Prentiss Smith & Co. Inc. increased its position in shares of GlycoMimetics by 42.9% in the 4th quarter. Prentiss Smith & Co. Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 3,000 shares during the last quarter. WINTON GROUP Ltd acquired a new position in GlycoMimetics during the third quarter valued at approximately $186,000. Voya Investment Management LLC acquired a new stake in GlycoMimetics in the second quarter valued at $205,000. Virtus ETF Advisers LLC increased its stake in GlycoMimetics by 3.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 29,862 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 1,057 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in GlycoMimetics by 44.2% in the third quarter. Alliancebernstein L.P. now owns 22,500 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 6,900 shares during the period.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company’s drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.

Featured Story: Stock Selection – What is cash flow?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GlycoMimetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlycoMimetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts